Klinikum Nürnberg

Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma (2022) Straka C, Schaefer-Eckart K, Hertenstein B, Bassermann F, Salwender H, Langer C, Kroenke J, et al. Conference contribution The effect of self-inflicted burns on ABSI score prediction power: A four-year prospective multicenter study of the German Burn Registry (2022) Billner M, Reif S, Registry GB, Reichert B Journal article Donor genetic determinant of thymopoiesis rs2204985 impacts clinical outcome after single HLA mismatched hematopoietic stem cell transplantation (2022) Tsamadou C, Gowdavally S, Platzbecker U, Sala E, Valerius T, Wagner-Drouet E, Wulf G, et al. Journal article Higher risk for chronic graft-versus-host disease (GvHD) in HLA-G mismatched transplants following allogeneic hematopoietic stem cell transplantation: A retrospective study (2022) Neuchel C, Gowdavally S, Tsamadou C, Platzbecker U, Sala E, Wagner-Drouet E, Valerius T, et al. Journal article Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/ Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis (2022) Nagler A, Ngoya M, Galimard JE, Labopin M, Bornhaeuser M, Stelljes M, Finke J, et al. Journal article Influence of sex on results and consequences of coronary fractional flow reserve in clinical practice: results of a prospective large-scale multicenter registry (2022) Tröbs M, Marwan M, Gaede L, Moellmann H, Giesler T, Rittger H, Rudolph T, et al. Conference contribution Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study) (2022) Rech J, Kleyer A, Ostergaard M, Hagen M, Mendez LV, Tascilar K, Krönke G, et al. Conference contribution Development of brain metastases and survival outcomes upon first-line systemic therapy in BRAF mutant and BRAF wildtype melanoma patients: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG (2022) Franklin C, Mohr P, Meier F, Weichenthal M, Grimmel-Mann I, Gutzmer R, Utikal JS, et al. Conference contribution Effectiveness and Safety of Dabrafenib and Trametinib in Patients with BRAFV600 Mutated Metastatic Melanoma in the Real-World Setting - Final Results of the Non-Interventional COMBI-r Study (2022) Berking C, Livingstone E, Weichenthal M, Leiter-Stoeppke U, Remy J, Eigentler T, Mohr P, et al. Conference contribution Amyloid-beta levels and cognitive trajectories in non-demented pTau181-positive subjects without amyloidopathy (2022) Oberstein T, Schmidt M, Florvaag A, Haas AL, Siegmann EM, Olm P, Utz J, et al. Journal article